news
Linagliptin recommended for approval in the treatment of type 2 diabetes
24 June 2011 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly received a positive opinion from the EMA's medicinal committee...
List view / Grid view
Eli Lilly & Company
news
BYDUREON™ receivies marketing authorisation in Europe
21 June 2011 | By Eli Lilly and Company
Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the European Commission has granted marketing authorization to BYDUREON™...
news
Patients with deadly form of lung cancer lived longer without disease worsening
5 June 2011 | By Eli Lilly and Company
Eli Lilly and Company announced that PARAMOUNT, met its primary endpoint of progression-free survival...
news
Amylin Pharmaceuticals files suit against Eli Lilly
17 May 2011 | By Amylin Pharmaceuticals
Complaint alleges anti-competitive activity and breach of strategic alliance agreements...
news
FDA approves linagliptin tablets for the treatment of type 2 diabetes
3 May 2011 | By OgilvyHealthPR
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.1 The FDA has approved linagliptin as a monotherapy…
news
Lilly and Medtronic announce drug-device collaboration for Parkinson’s Disease
27 April 2011 | By Eli Lilly & Company
Collaboration combines companies' expertise in neuroscience and targeted drug delivery...
news
Can personalised medicine save the pharma sector?
17 March 2011 | By GDS International
Personalised medicine is making a comeback – but will it stick this time?...
news
Janssen Pharmaceutica NV receives offer to acquire animal health business
14 March 2011 | By Janssen Pharmaceutica NV
Janssen Pharmaceutica NV has received an offer from Elanco to acquire its Janssen Animal Health business...
news
Biopharmaceutical industry changes & policies that encourage medical innovation are critical
9 March 2011 | By Eli Lilly and Company
According to John Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company...
news
Rodent models meeting need for reduced drug attrition rates
14 February 2011 | By GDS International
What are the strategies for reducing drug attrition rates in the clinic through the application of transgenic rodent models?...
news
Lilly announces senior leadership changes
11 February 2011 | By Eli Lilly and Company
Eli Lilly and Company have named Sue Mahony as senior vice president and president of Lilly Oncology...
news
Lilly CEO says industry, public policy must pave way for innovation
10 February 2011 | By Eli Lilly and Company
A new approach to research, along with public policies that support medical innovation, will help biopharmaceutical companies address stubborn diseases...
news
Cognizant Selected by Lilly to Deliver Commercial Operations Solutions to Enhance Sales and Marketing Effectiveness, Business Performance
20 January 2011 | By Brands2Life
Cognizant, announced that it has been selected by Eli Lilly and Company...
news
Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid(TM) (Florbetapir) NDA
20 January 2011 | By Eli Lilly and Company
The U.S. FDA Peripheral and Central Nervous System Drugs Advisory Committee decided today that it could not recommend approval of Amyvid™ (florbetapir) at this time...
news
U.S. Food and Drug Administration (FDA) votes to recommend non-approval of liprotamase
12 January 2011 | By Eli Lilly and Company
Eli Lilly announces that the FDA Gastrointestinal Drugs Advisory Committee has recommended that additional studies be conducted...
